Dipal Doshi - 13 Jan 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: President and CEO, Director
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol: TRDA
Transactions as of: 13 Jan 2022
Net transactions value: +$17,400
Form type: 4
Filing time: 18 Jan 2022, 17:01:09 UTC
Previous filing: 01 Nov 2021
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Options Exercise	$17,400	+10,000	+5.7%	$1.74^*	184,460	13 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRDA	Stock Option (Right to Buy)	Options Exercise	$0	-10,000	-2.4%	$0.000000	399,989	13 Jan 2022	Common Stock	10,000	$1.74	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of (i) 170,067 shares of common stock and (ii) 14,393 shares of restricted common stock issued upon early exercise of stock options.
F2	25% of the shares subject to this option vested and became exercisable on December 31, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.